Comincini CE, Wilches VJH, Castillo PMC

Language: Spanish
References: 15
Page: 1-9
PDF size: 426.97 Kb.

ABSTRACT

Introduction: The COVID-19 pandemic has represented an unprecedented health, economic and social catastrophe for the present generations. Despite health efforts, no effective pharmacological treatment is known, so biosecurity measures and vaccines are the main containment measures.
Objective: Describe the immunovirological and clinical characteristics of four of the main vaccines available in Colombia.
Methods: A bibliographic search of documents published in the period 2020-2021 was carried out. Keywords such as "DNA and RNA" vaccines were used; "COVID vaccines"; "COVID-19", "SARS-CoV-2" for the recovery of documents in databases such as SciELO, PubMed, Science Direct, among others.
Results: Pfizer and Moderna are mRNA vaccines with a 2-dose schedule and a third booster; the first with an effectiveness of 95%, the second between 82% and 95% depending on the age group. Some side effects of both vaccines can become myocarditis and pericarditis. AstraZeneca is a non-replicative viral vector vaccine, with 69% effectiveness and a two-dose schedule, with a possible booster. Some adverse effects reported are thromboembolic diseases, Guillain-Barré and transverse myelitis. CoronaVac is an inactivated SARS-CoV2 vaccine, with 54% effectiveness and 100% prevention of hospitalizations, and it is the newest of the vaccines developed and may present the same adverse effects as the previous ones. Specific contraindications were found for no vaccine. In Colombia, the most applied are Pfizer, AstraZeneca and Moderna.
Conclusions: Several vaccines against COVID-19 have been developed with different mechanisms of action. No absolute contraindications are reported that justify not being vaccinated; on the contrary, vaccination is the most promising bet to end the pandemic. It is necessary to promote strategies that increase the vaccination rate, especially in reluctant population groups.

REFERENCES

1. Salazar D, Uzquiano M, Rivera G, Velasco E. Mecanismos de transmisión delSARS-CoV-2. Acta Nov. 2020 [acceso 20/11/2021];9:773-92. Disponible en:http://www.scielo.org.bo/scielo.php?pid=S1683-07892020000200008&script=sci_arttext

2. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis:observations and hypotheses. Lancet 2020 [acceso 20/11/2021];395(10235):1517-20. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S014067362030920X

3. Cáceres Bermejo GG. Un momento de reflexión acerca de las vacunas. SanidMil 2012 [acceso 20/11/2021];68(2):109-14. Disponible en:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1887-85712012000200009&lng=en&nrm=iso&tlng=en

4. Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol 2021[acceso 20/11/2021];71:111-6. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S095279152100090X

5. Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. ComparingCOVID-19 vaccines for their characteristics, efficacy and effectiveness againstSARS-CoV-2 and variants of concern: A narrative review. Clin Microbiol Infect.2021 [acceso 21/11/2021] 28(2):202-21; Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S1198743X21006042

6. Fanelli D, Piazza F. Analysis and forecast of COVID-19 spreading in China, Italyand France. Chaos, Solitons & Fractals 2020 [acceso21/11/2021];134(109761):109761. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S0960077920301636

7. Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, etal. COVID-19 vaccine – Long term immune decline and breakthrough infections.Vaccine. 2021 [acceso 22/11/2021];39(48):6984-9. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S0264410X21013700

8. Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, NiesenMJM, et al. FDA-authorized mRNA COVID-19 vaccines are effective per real-worldevidence synthesized across a multi-state health system. Med. 2021 [acceso22/11/2021];2(8):979-92:e8. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S2666634021002385

9. Fragkou PC, Dimopoulou D. Serious complications of COVID-19 vaccines: Amini-review. Metab Open. 2021 [acceso 23/11/2021];12:100145. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S2589936821000694

10. Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. Afocused review on technologies, mechanisms, safety, and efficacy of availableCOVID-19 vaccines. Int Immunopharmacol. 2021 [acceso23/11/2021];100:108162. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S1567576921007980

11. Fujimori J, Miyazawa K, Nakashima I. Initial clinical manifestation ofmultiple sclerosis after immunization with the Pfizer-BioNTech COVID-19vaccine. J Neuroimmunol. 2021 [acceso 25/11/2021];361:577755. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S0165572821002824

12. Gorostiaga M. Caracterización de la línea celular VERO como sustrato para laproducción de vacunas virales [tesis doctoral]. [Buenos Aires (Argentina)]:Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales; 1999[acceso 25/11/2021]. Disponible en:https://bibliotecadigital.exactas.uba.ar/download/tesis/tesis_n3252_Gorostiaga.pdf

13. Ministerio de Salud y Protección Social. Vacunación contra COVID-19. Bogotá:Minsalud; 2021 [acceso 28/11/2021]. Disponible en:https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-COVID-19.aspx

14. HudExchange. La utilización de incentivos para mejorar la adherencia a lavacuna. Washington D.C; U.S. Department of Housing and Urban Development;2021 [acceso 29/11/2021]. Disponible en:https://files.hudexchange.info/resources/documents/Utilizing-Incentives-to-Increase-Vaccine-Adherence-Spanish.pdf

15. Volpp KG, Cannuscio CC. Incentives for Immunity - Strategies for IncreasingCOVID-19 Vaccine Uptake. N Engl J Med 2021 [acceso 27/11/2021];385(1):e1.Disponible en: http://www.nejm.org/doi/10.1056/NEJMp2107719